drugset / Trial / NCT01275222
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
Timeline
- Start
- 2002-11-13
- Primary completion
- 2008-09-03
- Completion
- 2008-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 20 mg | Oral |
| Subject | Imatinib | Small molecule | 600 mg | Oral |
| Subject | Imatinib | Small molecule | 800 mg | Oral |